Sirolimus for systemic lupus erythematosus

Affiliations

¹ Department of Clinical Immunology and Allergy, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia. Electronic address: hannah.hu@health.nsw.gov.au.
² Department of Clinical Immunology and Allergy, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.

Comment

Hannah Q Hu et al. Lancet. 2018.

. 2018 Sep 1;392(10149):733-734.

doi: 10.1016/S0140-6736(18)31792-6.

¹ Department of Clinical Immunology and Allergy, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia. Electronic address: hannah.hu@health.nsw.gov.au.
² Department of Clinical Immunology and Allergy, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.

No abstract available

Comment on

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.
Lai ZW, Kelly R, Winans T, Marchena I, Shadakshari A, Yu J, Dawood M, Garcia R, Tily H, Francis L, Faraone SV, Phillips PE, Perl A. Lai ZW, et al. Lancet. 2018 Mar 24;391(10126):1186-1196. doi: 10.1016/S0140-6736(18)30485-9. Epub 2018 Mar 15. Lancet. 2018. PMID: 29551338 Free PMC article. Clinical Trial.